Our Services
Medical Information
Helpful Resources
Published on: 1/9/2026
Nurtec, or rimegepant, is used for migraines in adults in two ways: it treats an acute migraine attack with or without aura, and it helps prevent episodic migraine when taken on a regular schedule. There are several factors to consider, including who should use it, dosing and how quickly it works, possible side effects, liver or kidney limits, pregnancy and breastfeeding questions, and drug interactions. See the complete answer below to understand more and decide on next steps with your clinician.
Nurtec (generic name: rimegepant) is an oral medication in the class of calcitonin gene-related peptide (CGRP) receptor antagonists. It is approved by the U.S. Food and Drug Administration (FDA) for two primary uses related to migraine:
Below is a detailed, plain-language overview of how Nurtec works, when and how it's used, safety considerations, and next steps you can take—including a free online tool to help determine if your symptoms match migraine patterns.
| Use | Dose | Frequency |
|---|---|---|
| Acute migraine attack | 75 mg orally (tablet dissolves on tongue) | Single dose; may repeat once after ≥2 hours if needed (max 150 mg/day) |
| Preventive therapy (episodic) | 75 mg orally | Every other day |
If you experience any of the following, seek medical attention immediately:
If you're experiencing headaches that significantly impact your daily life, understanding whether they're migraines is an important first step. Try Ubie's free AI-powered migraine symptom checker to quickly assess your symptoms and get personalized insights that you can discuss with your healthcare provider to determine if treatments like Nurtec may be right for you.
Finally, while Nurtec offers an effective option both for treating acute migraine attacks and preventing episodic migraine, speak to a doctor about any serious or life-threatening symptoms you experience. Only a healthcare professional can provide personalized advice, confirm a diagnosis, and ensure safe, effective treatment.
(References)
Ailani J, Lipton RB, Hutchinson S, et al. (2021). Rimegepant, an oral CGRP receptor antagonist, for migraine prevention… N Engl J Med, 33771649.
Kamath PS, & Wiesner RH. (2001). A model to predict survival in patients with end-stage liver disease. Hepatology, 11157951.
European Association for the Study of the Liver. (2018). EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 29847022.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.